Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL952110 | 1.00 | TACR1 (0.46) | TACR1SLC6A4 | |
| SCHEMBL12601426 | 1.00 | TACR1 (0.46) | TACR1SLC6A4 | |
| SCHEMBL14404453 | 1.00 | TACR1 (0.46) | TACR1SLC6A4 | |
| Hydrochloric Acid SCHEMBL956074 | 0.99 | TACR1 (0.46) | TACR1SLC6A4 | |
| Hydrochloric Acid SCHEMBL956073 | 0.99 | TACR1 (0.46) | TACR1SLC6A4 | |
| SCHEMBL12672586 | 0.94 | TACR1 (0.41) | TACR1SLC6A4 | |
| SCHEMBL4006725 | 0.90 | TACR1 (0.46) | TACR1SLC6A4 | |
| SCHEMBL4967159 | 0.90 | TACR1 (0.46) | TACR1SLC6A4 | |
| Hydrochloric Acid SCHEMBL4011840 | 0.89 | TACR1 (0.45) | TACR1SLC6A4 | |
| SCHEMBL12602183 | 0.85 | TACR1 (0.52) | TACR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580821-B2 | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety | HOFFMANN-LA ROCHE INC. (US) | 2013-11-12 | — | — | US | claimed |
| EP-2004605-B1 | PIPERIDINE DERIVATIVES USEFUL AS SEROTONIN TRANSPORTER INHIBITORS AND NEUROKININ-1 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-06-29 | — | — | EP | claimed |
| US-20110105561-A1 | SEROTONIN TRANSPORTER (SERT) INHIBITORS FOR THE TREATMENT OF DEPRESSION AND ANXIETY | GRUNDSCHOBER CHRISTOPHE | 2011-05-05 | — | — | US | claimed |
| US-20070232652-A1 | Serotonin transporter (sert) inhibitors for the treatment of depression and anxiety | HOFFMAN-LA ROCHE INC. | 2007-10-04 | — | — | US | claimed |
| US-8580821-B2 | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety | HOFFMANN-LA ROCHE INC. (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2004605-B1 | PIPERIDINE DERIVATIVES USEFUL AS SEROTONIN TRANSPORTER INHIBITORS AND NEUROKININ-1 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-06-29 | — | — | EP | disclosed |
| US-20110105561-A1 | SEROTONIN TRANSPORTER (SERT) INHIBITORS FOR THE TREATMENT OF DEPRESSION AND ANXIETY | GRUNDSCHOBER CHRISTOPHE | 2011-05-05 | — | — | US | disclosed |
| US-7872022-B2 | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety | HOFFMANN-LA ROCHE INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-20070232652-A1 | Serotonin transporter (sert) inhibitors for the treatment of depression and anxiety | HOFFMAN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105561-A1 | SEROTONIN TRANSPORTER (SERT) INHIBITORS FOR THE TREATMENT OF DEPRESSION AND ANXIETY | SLC6A4, SLC6A1, SLC1A2 | TACR1 71/4885SLC6A4 1/4885 |
| US-20070232652-A1 | Serotonin transporter (sert) inhibitors for the treatment of depression and anxiety | SLC6A4, SLC6A1, SLC1A2 | TACR1 71/4885SLC6A4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.